You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
瑞普生物(300119.SZ)取得新獸藥註冊證書
格隆匯 11-13 18:56

格隆匯11月13日丨瑞普生物(300119.SZ)公佈,根據《獸藥管理條例》和《獸藥註冊辦法》規定,公司近日獲得由農業農村部核發的三類《新獸藥註冊證書》。

新獸藥名稱:重組犬α-干擾素(凍幹型);研製單位:天津瑞普生物技術股份有限公司、北京中科拜克生物技術有限公司;註冊分類:三類;新獸藥註冊證書號:(2019)新獸藥證字64號。

干擾素(interferon,IFN)是一種細胞因子,它是機體感染病毒時,宿主細胞通過抗病毒應答反應,而產生的一組結構類似、功能相近的低分子糖蛋白。其中α-干擾素主要通過抑制病毒複製發揮其直接抗病毒活性,並激活和調節機體天然免疫與適應性免疫系統的細胞免疫功能,因此,病毒感染早期應用干擾素發揮其抗病毒活性、中後期應用干擾素發揮其免疫調節功能。

重組犬α-干擾素(凍幹型)系研究人員採用基因重組工程技術將犬α干擾素基因插入重組質粒中,構建重組大腸桿菌,經過單菌落篩選、DNA測序、表達驗證等方法最終研製出生產菌種,重組大腸桿菌菌種經高密度發酵、蛋白質提取和純化、經真空冷凍乾燥研製而成,是公司應用前沿生物工程技術、擁有自主知識產權的產品。

重組犬α-干擾素(凍幹型)作為一種重組生化藥物,與傳統提取類藥物相比,具有有效成分純度高、安全性好、批間穩定、可持續穩定供應等優勢,同時通過農業轉基因生物安全評價、多區域臨牀試驗驗證,證明本製品對犬安全、高效,可用於早期治療犬細小病毒性腸炎等病毒感染性疾病,為寵物臨牀醫師提供了一種新的用藥選擇。重組犬α-干擾素(凍幹型)項目從立項研製至獲批,歷經十幾年,標誌着我國首個重組獸用干擾素製品的誕生,成為公司寵物產品系列中的重要產品,對於提升寵物產品銷量有重要意義。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account